Quest Diagnostics Inc. (DGX)

106.51
0.29 0.27
NYSE : Health Services
Prev Close 106.22
Open 106.54
Day Low/High 106.16 / 106.92
52 Wk Low/High 78.95 / 108.76
Volume 54.29K
Avg Volume 907.80K
Exchange NYSE
Shares Outstanding 134.67M
Market Cap 14.31B
EPS 5.40
P/E Ratio 20.59
Div & Yield 2.12 (1.98%)
Jim Cramer -- 'The Real Market's Healthier,' So Ignore the Bears

Jim Cramer -- 'The Real Market's Healthier,' So Ignore the Bears

There is so much buying power in so many new areas.

Quest Diagnostics Becomes #40 Most Shorted S&P 500 Component, Replacing Dr Pepper Snapple Group

Quest Diagnostics Becomes #40 Most Shorted S&P 500 Component, Replacing Dr Pepper Snapple Group

The most recent short interest data has been released for the 05/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Laboratory Corp. of America Looks Pretty Healthy

LH's $5.7B Covance takeover could be just what the doctor ordered.

Quest Diagnostics Becomes #49 Most Shorted S&P 500 Component, Replacing Consolidated Edison

Quest Diagnostics Becomes #49 Most Shorted S&P 500 Component, Replacing Consolidated Edison

The most recent short interest data has been released for the 05/13/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

These 5 Rocket Stocks Look Ready for Blastoff in May

These 5 Rocket Stocks Look Ready for Blastoff in May

These stocks have both short-term gain catalysts and longer-term growth potential.

Analysts: Quest Likely to Do Deals First, Stock Buybacks Second, with Focus Sale Proceeds

Analysts: Quest Likely to Do Deals First, Stock Buybacks Second, with Focus Sale Proceeds

Quest Diagnostics in March agreed to sell Focus Diagnostics to DiaSorin SpA for $300 million.

Quest Diagnostics (DGX) Marked As A Barbarian At The Gate

Quest Diagnostics (DGX) Marked As A Barbarian At The Gate

Trade-Ideas LLC identified Quest Diagnostics (DGX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Ex-Dividends To Watch: 3 Stocks Going Ex-Dividend Monday: KYE, KRG, DGX

Ex-Dividends To Watch: 3 Stocks Going Ex-Dividend Monday: KYE, KRG, DGX

KYE KRG DGX are going ex-dividend Monday, Monday, April 04, 2016

Quest Diagnostics (DGX) Stock Higher, to Sell Focus Diagnostics Business to DiaSorin

Quest Diagnostics (DGX) Stock Higher, to Sell Focus Diagnostics Business to DiaSorin

Quest Diagnostics (DGX) stock is up on Wednesday morning as DiaSorin will buy the company’s immunodiagnostic and molecular diagnostic products business for $300 million.

Quest Diagnostics (DGX) Stock Receives ‘Neutral’ Rating at Credit Suisse

Quest Diagnostics (DGX) Stock Receives ‘Neutral’ Rating at Credit Suisse

Quest Diagnostics (DGX) stock coverage was initiated at Credit Suisse with a ‘neutral’ rating and $72 price target.

Drug Company Executives Make the Best Connections

Drug Company Executives Make the Best Connections

An analysis from business information service BoardEx shows that the CEOs of healthcare and pharma companies have professional networks about 30% larger than the average S&P 500 CEO network.

Post-Market Activity Shows Quest Diagnostics (DGX) Down

Post-Market Activity Shows Quest Diagnostics (DGX) Down

Trade-Ideas LLC identified Quest Diagnostics (DGX) as a post-market laggard candidate

3 Stocks With Upcoming Ex-Dividend Dates: LGI, GBCI, DGX

3 Stocks With Upcoming Ex-Dividend Dates: LGI, GBCI, DGX

LGI GBCI DGX are going ex-dividend tomorrow, Friday, January 08, 2016

Here Are the 10 Directors You Want on Your Company’s Board

Here Are the 10 Directors You Want on Your Company’s Board

Few of these people, save Facebook's Sheryl Sandberg, are household names, but they've all served on multiple boards whose stocks have trounced the market.

Happiness for Iconix is a new Peanuts movie

Happiness for Iconix is a new Peanuts movie

Iconix Brands has big hopes for new Peanuts film

5 Rocket Stocks to Pick Up for Fall Gains

5 Rocket Stocks to Pick Up for Fall Gains

These stocks have both short-term gain catalysts and longer-term growth potential.

Newman Ferrara Announces Class Action Against Quest Diagnostics Following Patient Medical Data Breach

Newman Ferrara Announces Class Action Against Quest Diagnostics Following Patient Medical Data Breach

Newman Ferrara LLP announced today that on November 16, 2015, the firm filed a class action lawsuit in the United States District Court for the Southern District of New York against Quest Diagnostics, Inc.

Quest Diagnostics Is on a Mission to Rally

Quest Diagnostics Is on a Mission to Rally

Charts show DGX should break out above resistance soon.

Quest Diagnostics (DGX) Falls Further As It's Water-Logged And Getting Wetter

Quest Diagnostics (DGX) Falls Further As It's Water-Logged And Getting Wetter

Trade-Ideas LLC identified Quest Diagnostics (DGX) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Theranos Must Refute Claims Specifically

Questions will continue to swirl until facts emerge.

Analysts' Actions -- Allstate, AthenaHealth, Quest Diagnostics, Blackstone

Analysts' Actions -- Allstate, AthenaHealth, Quest Diagnostics, Blackstone

Here are Friday's top research calls, including changes at Allstate, AthenaHealth, Quest Diagnostics and Blackstone.

Dividend Watch: 3 Stocks Going Ex-Dividend Tomorrow: FSFR, KRG, DGX

Dividend Watch: 3 Stocks Going Ex-Dividend Tomorrow: FSFR, KRG, DGX

FSFR KRG DGX are going ex-dividend tomorrow, Friday, October 02, 2015

Quest Diagnostics (DGX) Is Today's Water-Logged And Getting Wetter Stock

Quest Diagnostics (DGX) Is Today's Water-Logged And Getting Wetter Stock

Trade-Ideas LLC identified Quest Diagnostics (DGX) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Quest Diagnostics (DGX) Faces a 10% Decline

Quest Diagnostics (DGX) Faces a 10% Decline

Quest Diagnostics (DGX) could be vulnerable to a deep correction, but a decline to the next support around $60 seems like the path of least resistance.

Quest Diagnostics Can't Stop the Bleeding; 10% Slide in Sight

Quest could be vulnerable to a deep correction, but a decline to next support around $60 seems like the path of least resistance. 

5 Big Stocks That Everyone Hates -- but You Should Love

5 Big Stocks That Everyone Hates -- but You Should Love

These heavily shorted stocks could get squeezed much higher on any positive catalyst.

5 Hated Stocks That Could Pop This Summer

5 Hated Stocks That Could Pop This Summer

These heavily shorted stocks could get squeezed much higher on any positive catalyst.

'Fast Money' Recap: Thinking About a Large-Scale Market Correction?

'Fast Money' Recap: Thinking About a Large-Scale Market Correction?

The trading panel discussed China's stock market, how Apple is affected and whether to stay in social media stocks.

Quest Diagnostics (DGX) Marked As A Barbarian At The Gate

Quest Diagnostics (DGX) Marked As A Barbarian At The Gate

Trade-Ideas LLC identified Quest Diagnostics (DGX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

3 Stocks Going Ex-Dividend Monday: NYRT, DGX, LEN

3 Stocks Going Ex-Dividend Monday: NYRT, DGX, LEN

NYRT DGX LEN are going ex-dividend Monday, Monday, July 06, 2015

TheStreet Quant Rating: B+ (Buy)